DexCom, Inc. (DXCM) Forecasted to Earn FY2017 Earnings of ($0.62) Per Share

DexCom, Inc. (NASDAQ:DXCM) – Oppenheimer decreased their FY2017 earnings per share estimates for DexCom in a report released on Monday. Oppenheimer analyst S. Lichtman now anticipates that the medical device company will post earnings per share of ($0.62) for the year, down from their prior estimate of ($0.61). Oppenheimer currently has a “Buy” rating and a $67.00 target price on the stock. Oppenheimer also issued estimates for DexCom’s Q4 2017 earnings at $0.07 EPS, Q2 2018 earnings at ($0.17) EPS and FY2018 earnings at ($0.41) EPS.

A number of other equities analysts also recently commented on the company. Zacks Investment Research downgraded DexCom from a “hold” rating to a “sell” rating in a report on Tuesday, October 24th. Morgan Stanley dropped their target price on DexCom from $72.00 to $52.00 and set a “neutral” rating on the stock in a report on Friday, November 3rd. TheStreet downgraded DexCom from a “c-” rating to a “d+” rating in a report on Wednesday, October 25th. BidaskClub upgraded DexCom from a “buy” rating to a “strong-buy” rating in a report on Tuesday, December 12th. Finally, Northland Securities reiterated a “sell” rating and set a $40.00 target price on shares of DexCom in a report on Tuesday, January 16th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $67.44.

DexCom (NASDAQ:DXCM) opened at $54.67 on Wednesday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86. DexCom has a twelve month low of $42.62 and a twelve month high of $86.32.

Hedge funds and other institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company grew its position in shares of DexCom by 12.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock worth $238,000 after acquiring an additional 354 shares in the last quarter. Advisor Group Inc. grew its position in shares of DexCom by 104.9% in the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after acquiring an additional 837 shares in the last quarter. Amalgamated Bank grew its position in shares of DexCom by 5.7% in the 4th quarter. Amalgamated Bank now owns 17,107 shares of the medical device company’s stock worth $982,000 after acquiring an additional 924 shares in the last quarter. Wedbush Securities Inc. grew its position in shares of DexCom by 24.2% in the 4th quarter. Wedbush Securities Inc. now owns 5,589 shares of the medical device company’s stock worth $321,000 after acquiring an additional 1,089 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of DexCom by 0.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 127,769 shares of the medical device company’s stock worth $6,247,000 after acquiring an additional 1,095 shares in the last quarter.

In other DexCom news, insider Terrance H. Gregg sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $56.86, for a total transaction of $568,600.00. Following the completion of the sale, the insider now owns 484,559 shares in the company, valued at approximately $27,552,024.74. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Richard Doubleday sold 1,635 shares of the firm’s stock in a transaction that occurred on Friday, November 24th. The shares were sold at an average price of $55.53, for a total value of $90,791.55. Following the sale, the executive vice president now owns 65,049 shares of the company’s stock, valued at approximately $3,612,170.97. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,140 shares of company stock valued at $2,743,281. 1.70% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: “DexCom, Inc. (DXCM) Forecasted to Earn FY2017 Earnings of ($0.62) Per Share” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/14/dexcom-inc-dxcm-forecasted-to-earn-fy2017-earnings-of-0-62-per-share.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply